Integra Lifesciences Holdings CORP

Integra LifeSciences announced its second quarter 2026 financial results, showing modest revenue growth and improved earnings per share, while updating its full-year revenue guidance due to foreign exchange impacts.

Integra LifeSciences announced the appointment of Dr. Stuart Essig as President and CEO, effective May 1, 2026, succeeding Mojdeh Poul.

Integra LifeSciences reported strong first quarter 2026 results, exceeding expectations with increased revenues and improved profitability, while also raising full-year adjusted EPS guidance.

Integra LifeSciences has amended its $150 million accounts receivable securitization facility, extending the maturity date to April 10, 2029.

Integra LifeSciences reported a GAAP net loss for full-year 2025 driven by a significant goodwill impairment, alongside a decline in Q4 2025 revenues and adjusted earnings, while providing cautious 2026 guidance.

Integra LifeSciences Holdings Corporation has adopted a new Change in Control Severance Program for key executives, effective January 1, 2026.

Integra LifeSciences Holdings Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net income of $4.5 million.

Integra LifeSciences Holdings Corporation announced its first quarter 2026 financial results, reporting a reduced net loss compared to the prior year, driven by improved operational performance and revenue growth.

Integra LifeSciences reported a significant net loss for the nine months ended September 30, 2025, primarily due to a $511.4 million goodwill impairment charge and ongoing operational challenges, despite a slight increase in total revenue.

Integra LifeSciences Holdings Corporation reported a substantial net loss for the second quarter and first half of 2025, primarily driven by a $511.4 million goodwill impairment charge, alongside declining gross margins and negative operating cash flow.

Integra LifeSciences' Q1 2025 results reveal a net loss, influenced by quality and operational challenges, despite revenue increase driven by the Acclarent acquisition.

Integra LifeSciences experienced a net loss in Q3 2024, impacted by acquisition costs and operational issues, despite a slight revenue decrease.

Integra LifeSciences reported a significant net loss of $516.5 million for 2025, primarily due to a $511.4 million goodwill impairment charge, alongside ongoing quality system challenges and increased tariff costs.

Integra LifeSciences' 2024 results reflect revenue growth driven by the Acclarent acquisition, offset by quality and operational issues, resulting in a net loss for the year.

Integra LifeSciences' 10-K filing provides a comprehensive overview of the company's business, financial performance, strategic initiatives, and potential risks for the fiscal year ended December 31, 2023.

Jeffrey Mosebrook, SVP of Integra Lifesciences, reported a transaction involving the acquisition of common stock.

Harvinder Singh, EVP & President, SS at Integra LifeSciences Holdings Corp, was granted 5,590 restricted stock units.

Robert T. Davis Jr., EVP & President of TR&DT at Integra LifeSciences, was granted 11,180 restricted stock units.

Michael J. McBreen, EVP & Chief Commercial Officer at Integra LifeSciences Holdings Corp., was granted stock options and restricted stock units.

Integra Lifesciences Holdings Corp. reports the grant of stock options and restricted stock units to President and CEO Stuart Essig, with vesting schedules tied to continued service.

Barbara B. Hill, a Director at Integra LifeSciences Holdings Corp. (IART), reported the acquisition of 6,638 and 17,700 shares of common stock on May 7, 2026.

Integra LifeSciences Holdings Corporation announced its 2026 Annual Meeting of Stockholders, set for May 7, 2026, to elect directors, ratify auditors, and approve executive compensation and an equity incentive plan amendment.

Integra LifeSciences' proxy statement outlines the company's 2024 performance, strategic initiatives, and executive compensation, while addressing operational challenges and future growth plans.

Integra LifeSciences is asking stockholders to approve amendments to its corporate charter and equity incentive plan at the upcoming annual meeting.

Vanguard Portfolio Management has reported beneficial ownership of 5.02% of Integra LifeSciences Holdings Corp. common stock as of June 30, 2026.

Paradigm Capital Management, Inc. has reported beneficial ownership of 5.2% of Integra Lifesciences Holdings Corp. common stock as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Integra LifeSciences Holdings Corp following an internal realignment.

Fuller & Thaler Asset Management, Inc. has updated its beneficial ownership in Integra LifeSciences Holdings Corp., reporting a 4.67% stake as of December 31, 2025.

Invesco Ltd. has reported a 4.5% beneficial ownership stake in Integra LifeSciences Holdings Corp. as a passive institutional investor.

Morgan Stanley has reduced its beneficial ownership in Integra LifeSciences Holdings Corp. to 4.3%, falling below the 5% threshold.